Samsung Bioepis, a Korean-based biopharmaceutical company, announced on Nov. 20, 2017 that its biosimilar, Ontruzant, which references Roche s Herceptin (trastuzumab), has received European regulatory approval for the treatment of early breast cancer, metastatic breast cancer, and metastaticOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.